PCSK9 inhibition across a wide spectrum of patients: One size fits all?Aug. 26, 2017 - Barcelona, Spain - G. Kees Hovingh, MD, AMC, Amsterdam, The Netherlands - PACE-CME symposium at ESC 2017
This lecture was part of a CME accredited symposium: PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies held at ESC 2017 in Barcelona
Video navigation menu
- Another milestone on the roadmap towards the acceptance of the LDL-hypothesis 0:24
- Effects of treatement with PCSK9 1:44
- LDL-c lowering by PCSK9 inhibition in HoFH patients and the effect on apheresis treatment 5:29
- Real-world experience with PCSK9 inhibition in HeFH patients 7:07
- Other insights gained from the PCSK9 antibody clinical trial programs 9:11
- Other approaches to inhibit PCSK9 include siRNAs, vaccins, adnectins and small molecules 12:06
The educational objectives of the symposium were to:
- Understand the unmet need for additional LDL-C-lowering therapies beyond current optimal statin-based therapy as a strategy for addressing lipid-related CV risk in patients at increased CV risk and with FH
- Understand the mechanisms and potential applications of emerging therapies to lower LDL through novel approaches that can be used in combination with statin therapy
- Describe the potential impact of PCSK9-based therapies in development in patients who require additional LDL-C reduction
- To explore treatment options in a statin-intolerant high risk patient in order to reach LDL-C goal
- Compare and evaluate evidence from recent clinical trials of novel agents in clinical development and assess their impact on lipids and cardiovascular risk
- Emphasize the need for outcomes data from clinical trials to apply implications and recommendations for practical lipid management
- Understand the implications of new ESC guidelines for lipid management
Kees Hovingh, MD is an internist and vascular medicine specialist at the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, the Netherlands and visiting professor at Imperial college in London, UK. Hovingh is co-chair of the department of internal medicine at the AMC and in his role as head of the clinical trial unit involved in a large number of clinical trials, mainly focused on novel therapies to combat (the consequences of) dyslipidemia.
This programme was accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).
This symposium was supported by unrestricted educational grant provided by Amgen and Sanofi-Regeneron
The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-CME.